Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 79, Issue 5, Pages 789-800
Publisher
Wiley
Online
2014-11-06
DOI
10.1111/bcp.12542
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Scientific Basis of Body Surface Area–Based Dosing
- (2014) E Chatelut et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Conventional Dosing of Anticancer Agents: Precisely Wrong or Just Inaccurate?
- (2014) S Bins et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer
- (2013) Michelle A. Rudek et al. BREAST CANCER RESEARCH AND TREATMENT
- Proteasome inhibitors in the treatment of multiple myeloma
- (2013) Ali McBride et al. Expert Review of Anticancer Therapy
- An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
- (2012) R. Vij et al. BLOOD
- Proteasome inhibitors in multiple myeloma: 10 years later
- (2012) P. Moreau et al. BLOOD
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- Body-Surface Area–Based Chemotherapy Dosing: Appropriate in the 21st Century?
- (2012) Jan H. Beumer et al. JOURNAL OF CLINICAL ONCOLOGY
- Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
- (2012) Jesús F. San Miguel et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
- (2011) D. E. Reece et al. BLOOD
- Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies
- (2011) E. C. Lee et al. CLINICAL CANCER RESEARCH
- Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
- (2011) Bertrand Coiffier et al. LANCET ONCOLOGY
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Managing multiple myeloma in the elderly: are we making progress?
- (2011) Hang Quach et al. Expert Review of Hematology
- Renal Insufficiency and Failure
- (2011) M. A. Dimopoulos et al. Hematology-American Society of Hematology Education Program
- Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma
- (2010) Donna E. Reece et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
- (2010) E. Kupperman et al. CANCER RESEARCH
- Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
- (2010) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions
- (2009) Radojka M. Savic et al. AAPS Journal
- Pharmacokinetics and dosage adjustment in patients with renal dysfunction
- (2009) Roger K. Verbeeck et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Emerging Evidence of the Impact of Kidney Disease on Drug Metabolism and Transport
- (2008) TD Nolin et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now